FLC Capital Advisors Has $1.26 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

FLC Capital Advisors increased its position in shares of Pfizer Inc. (NYSE:PFE) by 22.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,611 shares of the biopharmaceutical company’s stock after purchasing an additional 8,839 shares during the quarter. FLC Capital Advisors’ holdings in Pfizer were worth $1,263,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans increased its stake in shares of Pfizer by 2.8% in the 2nd quarter. Thrivent Financial for Lutherans now owns 739,236 shares of the biopharmaceutical company’s stock valued at $20,684,000 after buying an additional 20,140 shares during the period. Sompo Asset Management Co. Ltd. boosted its stake in shares of Pfizer by 15.1% in the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 22,470 shares of the biopharmaceutical company’s stock valued at $629,000 after purchasing an additional 2,950 shares during the last quarter. Schwerin Boyle Capital Management Inc. grew its position in shares of Pfizer by 8.2% during the 2nd quarter. Schwerin Boyle Capital Management Inc. now owns 775,125 shares of the biopharmaceutical company’s stock worth $21,688,000 after buying an additional 58,850 shares during the period. Kowal Investment Group LLC raised its stake in shares of Pfizer by 10.3% during the second quarter. Kowal Investment Group LLC now owns 18,834 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 1,757 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Pfizer by 7.3% in the second quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company’s stock valued at $23,661,000 after buying an additional 57,825 shares during the period. 68.36% of the stock is owned by institutional investors.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on PFE. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Trading Down 0.7 %

PFE opened at $26.30 on Monday. The stock has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm’s fifty day simple moving average is $26.08 and its 200 day simple moving average is $27.99.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the prior year, the firm earned ($0.17) earnings per share. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.